Stop Wegovy or Ozempic at least 2 months before conception, and Mounjaro at least 1 month prior
Current clinical data shows GLP-1 receptor agonists produce meaningful weight loss in many patients, yet 20-30% experience minimal response, suggesting personalization matters significantly
Facundo Nogueira, head of the Sleep Laboratory at Hospital de Clnicas, told Infobae that the drug has, in general, a very good safety profile, with few serious adverse effects reported
The study also found major differences between men and women
A new method for measuring daytime sleepiness: the Epworth sleepiness scale
How Sleep Boosts Semaglutide and Tirzepatide Effectiveness Does Sleep Affect Semaglutide Results